IL-6 and IL-6R
Alpha Lifetech can provide IL-6 and IL-6R corresponding products, help each customer's research and development.
01
Introduction To IL-6 and IL-6R
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to IL6 and IL-6R protein is a common target in medicine.
IL-6, also known as IFN- β2, hepatocyte stimulating factor and hybridoma/plasmacytoma growth factor, is a 25-kDa secreting glycopeptide monocytes and macrophages that are the major producers of IL-6. IL-6 is a 212-amino acid single-stranded protein located on chromosome 7, where IL-6 and IL-6R α bind to form a complex associating with the gp 130 homodimer. The interleukin-6 receptor alpha (IL-6RA) is the α subunit of the IL-6 receptor and is also shared with other interleukin receptors. IL-6RA is a type I transmembrane glycoprotein that forms a complex with the type I transcellular signal transduction protein glycoprotein 130 (CD130) that modulates the biological activity of IL-6 with low affinity.
Function of Target IL-6 and IL-6R
IL-6T is produced by or after stimulation by cells, B cells, hepatocytes, endothelial cells, fibroblasts, keratinocytes, mesangial cells adipocytes, and several tumor cells. IL-6 is a class of cytokines produced by and acting on a variety of cells. Pro-inflammatory and anti-inflammatory cytokines are involved in various biological processes. It is originally produced by leukocytes and functions among leukocytes.IL-6 is a cytokine with pleiotropic activity, which can promote the proliferation and differentiation of a variety of cells and can also accelerate the synthesis of acute phase proteins in hepatocytes. It can also inhibit the growth of the M1 myeloid leukemia cell line, promote its maturation and differentiation, and inhibit the growth of melanoma and breast cancer cells.
Gene Pathway of Target IL-6 and IL-6R
In the classical signaling cascade, only cells expressing the transmembrane 80-kDa α receptor subunit IL-6R are responsive to IL-6. The monomeric complex of IL-6 and mIL-6R binds to the ubiquitously expressed 130-kDa β receptor subunit receptor (gp 130, CD130) and leads to gp 130 dimerization. The soluble form of sIL-6R can be constructed in complex with IL-6 and gp 130. Both ways to produce sIL-6R: sIL-6R can not only bind its ligand IL-6, but also the IL-6 and sIL-6R complex can bind and activate gp 130 on cells that do not carry membrane-bound IL-6R. This process is called IL-6 trans-signaling, which enhances the IL-6 target cell profile and explains the pleiotropic function of IL-6. After DC interaction with the antigen, IL-6, which is already intracellularly bound with IL-6R in DC, is presented to the plasma membrane in trans. Then, the membrane-bound IL-6 / mIL-6R complex on DC interacts with gp 130 on T cells to induce the production of pathogenic Th 17 cells and to inhibit Treg cells via IL-27.
Fig 1: IL-6 Gene Pathway. (Reference source: Kong E, Sucic S, Monje FJ, Savalli G, et al,. STAT3 controls IL6-dependent regulation of serotonin transporter function and depression-like behavior. Sci Rep. 2015 Mar 11;5:9009.)
Alpha Lifetech Can Provide
Currently, various immune drugs targeting IL6 and IL-6R targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. The IL6 and IL-6R targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, IL6 and IL-6R target products are also essential in medical research. Alpha Lifetech can provide IL6 and IL-6R corresponding products and help each customer's research and development. In addition, Alpha Lifetech also provides advanced expression systems and purification services to accelerate antibody research and development. Our synthesized antibody expression undergoes rigorous quality validation, including sequencing validation and functional expression analysis, to ensure high fidelity and performance. In addition, Alpha Lifetech provides customized solutions for recombinant proteins, such as codon optimization, promoter selection, and vector design, supplemented by downstream applications such as protein expression analysis to meet specific experimental needs.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ADT1703 | ADT1703-Vobarilizumab Biosimilar-Anti IL6R/CD126/ALB mAb- Research Grade |
1mg,5mg |
| ADT1595 | ADT1595-Sirukumab Biosimilar-Anti IL6 mAb- Research Grade | 100ug,1mg,5mg |
| ADT1727 | ADT1727-Ziltivekimab Biosimilar-Anti IL6mAb- Research Grade | 100ug,1mg,5mg |
| ADT1137 | ADT1137-Clazakizumab Biosimilar-Anti IL6mAb- Research Grade | 100ug,1mg,5mg |
| ADT1202 | ADT1202-Elsilimomab Biosimilar-Anti IL6 mAb- Research Grade | 1mg,5mg |
| ADT1461 | ADT1461-Olokizumab Biosimilar-Anti IL6 mAb- Research Grade | 100ug,1mg,5mg |
| ADT1590 | ADT1590-Siltuximab Biosimilar-Anti IL6 mAb- Research Grade | 1mg,5mg |
| ADT1574 | ADT1574-Sarilumab Biosimilar-Anti IL6R/CD126 mAb- Research Grade | 1mg,5mg |
| ADT1356 | ADT1356-Levilimab Biosimilar-Anti IL6R mAb- Research Grade | 100ug,1mg,5mg |
| ADT1576 | ADT1576-Satralizumab Biosimilar-Anti IL6R mAb- Research Grade | 1mg,5mg |
Reference
[1] Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020 May 4;217(5):e20190347.
[2] Uciechowski P, Dempke WCM. Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020;98(3):131-137.
[3] Malysch T, Reinhold JM, Becker CA, Schmidt-Bleek K, Kleber C. In vivo immunomodulation of IL6 signaling in a murine multiple trauma model. Immunol Res. 2023 Apr;71(2):164-172.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102